CT130, a semaglutide-derived GLP-1R agonist engineered for biweekly dosing, achieved superior metabolic outcomes compared to weekly semaglutide across multiple preclinical models. With an EC50 of 21 pM and half-life of 13.9 hours (1.4-fold longer than semaglutide), CT130 delivered greater reductions in body weight, LDL-C, total cholesterol, glucose tolerance, and body fat percentage in ob/ob and diet-induced obese mice. Critically, its drug-free intervals permitted near-complete GLP-1R recycling back to the cell surface — a mechanism the researchers term 'GLP-1R recovery' — whereas continuous semaglutide exposure drove progressive receptor internalization and downregulation. CT130 also reduced constipation risk and uniquely suppressed SREBP-2, upregulating LDLR without triggering compensatory PCSK9 induction, promoting fecal cholesterol excretion through a bile-acid-independent pathway.
The receptor homeostasis concept here is genuinely novel and mechanistically compelling. Chronic GLP-1R agonism is known to blunt receptor sensitivity over time — a likely contributor to the efficacy plateaus observed clinically with semaglutide. Engineering dosing intervals to allow receptor resensitization is an elegant pharmacological strategy that borrows from intermittent hormone physiology. The SREBP-2/LDLR/PCSK9 dissociation is particularly intriguing, potentially offering additive cardiovascular benefit beyond weight loss. However, all efficacy data are rodent-derived, with only a small primate safety pilot reported. Human pharmacokinetics, receptor recycling kinetics, and GI tolerability comparisons remain untested. This is promising preclinical science, but clinical translation is years away. Incremental in design heritage, potentially paradigm-shifting in receptor management strategy.